|
Sunshine Guojian Pharmaceutical Co., Ltd (688336.SS) DCF -Bewertung |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS) Bundle
Möchten Sie den inneren Wert von Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. beurteilen? Unser DCF-Taschenrechner (688336S) integriert reale Daten mit umfassenden Anpassungsoptionen, sodass Sie Prognosen anpassen und fundiertere Investitionsentscheidungen treffen können.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 655.0 | 928.8 | 825.5 | 1,014.0 | 1,193.6 | 1,406.1 | 1,656.5 | 1,951.4 | 2,298.9 | 2,708.2 |
| Revenue Growth, % | 0 | 41.8 | -11.12 | 22.84 | 17.7 | 17.81 | 17.81 | 17.81 | 17.81 | 17.81 |
| EBITDA | -97.3 | 62.1 | 168.2 | 424.7 | 836.8 | 349.3 | 411.4 | 484.7 | 571.0 | 672.7 |
| EBITDA, % | -14.86 | 6.69 | 20.37 | 41.88 | 70.11 | 24.84 | 24.84 | 24.84 | 24.84 | 24.84 |
| Depreciation | 136.0 | 135.5 | 122.4 | 96.1 | 128.0 | 197.9 | 233.2 | 274.7 | 323.6 | 381.2 |
| Depreciation, % | 20.77 | 14.58 | 14.83 | 9.48 | 10.72 | 14.08 | 14.08 | 14.08 | 14.08 | 14.08 |
| EBIT | -233.4 | -73.3 | 45.8 | 328.6 | 708.8 | 151.3 | 178.3 | 210.0 | 247.4 | 291.5 |
| EBIT, % | -35.63 | -7.89 | 5.54 | 32.41 | 59.39 | 10.76 | 10.76 | 10.76 | 10.76 | 10.76 |
| Total Cash | 2,710.8 | 2,365.8 | 2,577.1 | 1,881.3 | 1,370.0 | 1,406.1 | 1,656.5 | 1,951.4 | 2,298.9 | 2,708.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 102.9 | 257.0 | 149.4 | 136.7 | 147.2 | 245.5 | 289.2 | 340.7 | 401.3 | 472.8 |
| Account Receivables, % | 15.71 | 27.67 | 18.09 | 13.48 | 12.33 | 17.46 | 17.46 | 17.46 | 17.46 | 17.46 |
| Inventories | 225.1 | 210.1 | 227.0 | 195.0 | 229.6 | 345.8 | 407.3 | 479.8 | 565.3 | 665.9 |
| Inventories, % | 34.36 | 22.62 | 27.5 | 19.23 | 19.24 | 24.59 | 24.59 | 24.59 | 24.59 | 24.59 |
| Accounts Payable | 21.4 | 16.3 | 15.9 | 21.9 | 35.0 | 33.8 | 39.9 | 47.0 | 55.3 | 65.2 |
| Accounts Payable, % | 3.26 | 1.75 | 1.93 | 2.16 | 2.93 | 2.41 | 2.41 | 2.41 | 2.41 | 2.41 |
| Capital Expenditure | -227.0 | -263.8 | -221.3 | -235.7 | -280.8 | -384.2 | -452.7 | -533.3 | -628.2 | -740.1 |
| Capital Expenditure, % | -34.65 | -28.4 | -26.8 | -23.25 | -23.52 | -27.33 | -27.33 | -27.33 | -27.33 | -27.33 |
| Tax Rate, % | 0.4347 | 0.4347 | 0.4347 | 0.4347 | 0.4347 | 0.4347 | 0.4347 | 0.4347 | 0.4347 | 0.4347 |
| EBITAT | -194.9 | -2.3 | 77.9 | 311.7 | 705.7 | 115.4 | 135.9 | 160.1 | 188.6 | 222.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -592.4 | -274.9 | 69.5 | 222.7 | 520.9 | -286.5 | -182.9 | -215.4 | -253.8 | -299.0 |
| WACC, % | 5.88 | 5.87 | 5.88 | 5.88 | 5.88 | 5.88 | 5.88 | 5.88 | 5.88 | 5.88 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,041.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -305 | |||||||||
| Terminal Value | -7,865 | |||||||||
| Present Terminal Value | -5,912 | |||||||||
| Enterprise Value | -6,954 | |||||||||
| Net Debt | -409 | |||||||||
| Equity Value | -6,544 | |||||||||
| Diluted Shares Outstanding, MM | 617 | |||||||||
| Equity Value Per Share | -10.61 |
Benefits You Will Receive
- Authentic Financial Data: Comprehensive financial metrics – from revenue to EBIT – based on real and projected data for Sunshine Guojian Pharmaceutical (688336SS).
- Complete Customization: Modify all essential parameters (yellow cells) such as WACC, growth rates, and tax percentages.
- Instant Valuation Revisions: Automatic recalculations that allow you to assess the effects of modifications on Sunshine Guojian Pharmaceutical’s fair value.
- Flexible Excel Template: Designed for easy adjustments, scenario analysis, and in-depth forecasts.
- Efficient and Precise: Eliminate the need to build models from the ground up while ensuring accuracy and adaptability.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Sunshine Guojian Pharmaceutical (688336SS).
- WACC Calculation Tool: Comes with a pre-configured Weighted Average Cost of Capital sheet that allows for customizable inputs.
- Adjustable Forecast Assumptions: Easily modify projections for growth rates, capital expenditures, and discount rates.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specific to Sunshine Guojian Pharmaceutical (688336SS).
- Visual Dashboard and Charts: Clear visual representations summarize essential valuation metrics for straightforward analysis.
How It Functions
- Download: Obtain the pre-prepared Excel file containing Sunshine Guojian Pharmaceutical's financial data (688336SS).
- Customize: Modify forecasts such as revenue growth, EBITDA percentage, and WACC to suit your analysis.
- Real-Time Updates: Automatically adjust intrinsic value and NPV calculations as changes are made.
- Scenario Testing: Generate various projections and instantly compare different outcomes.
- Informed Decisions: Leverage the valuation results to inform and refine your investment strategy.
Why Choose This Calculator for Sunshine Guojian Pharmaceutical (688336SS)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Easily adjust variables to suit your analysis needs.
- Real-Time Valuation: Observe immediate changes to Sunshine Guojian's valuation as you modify inputs.
- Preloaded Financial Data: Comes with Sunshine Guojian’s actual financial metrics for swift evaluations.
- Relied Upon by Experts: Preferred by investors and analysts for making well-informed choices.
Who Can Benefit from This Product?
- Pharmaceutical Students: Gain hands-on experience in valuation methods with real industry data.
- Researchers: Integrate advanced financial models into your academic projects or studies.
- Investors: Evaluate your investment strategies and analyze valuation scenarios for Sunshine Guojian Pharmaceutical (688336SS).
- Market Analysts: Enhance your efficiency with a customizable, pre-designed DCF model tailored for the pharmaceutical sector.
- Entrepreneurs: Discover how large pharmaceutical companies like Sunshine Guojian Pharmaceutical (688336SS) are assessed in the market.
Contents of the Template
- Historical Data: Comprises Sunshine Guojian Pharmaceutical's past financial performance and initial forecasts.
- DCF and Levered DCF Models: Comprehensive templates to assess the intrinsic value of Sunshine Guojian Pharmaceutical (688336SS).
- WACC Sheet: Ready-to-use calculations for the Weighted Average Cost of Capital.
- Editable Inputs: Customize key parameters such as growth rates, EBITDA margins, and CAPEX projections.
- Quarterly and Annual Statements: An exhaustive overview of Sunshine Guojian Pharmaceutical's financial data.
- Interactive Dashboard: Dynamically visualize valuation outcomes and forecasts.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.